Molecular Detection (MDI) and Palex Medical entered into an exclusive distribution agreement for MDI's Detect-Ready™ MRSA assay in Spain. The kit is a qualitative real-time PCR in vitro diagnostic test for the direct detection of MRSA nasal colonization to aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.
The technology in the Detect-Ready kits provides a unique differential diagnosis engine that produces highly accurate results, minimizing the false positives and false negatives experienced with other MRSA screening kits, according to MDI. The assay's premixed reagents only require the addition of patient sample to run the test, which provides results in less than three hours, the company states.
Detect-Ready kits are off-the-shelf, room temperature-stabilized, and require no refrigeration. They are compatible with multiple real-time PCR platforms currently found in clinical laboratories, including the Roche LightCycler®, Qiagen Rotor-Gene®, and Cepheid SmartCycler®.
“Spain is introducing proactive control programs to combat the major problem that MRSA infections pose to health facilities worldwide, and we believe that the combination of accuracy, speed, versatility, and cost-effectiveness of the Detect-Ready MRSA assay will contribute to the success of these efforts,” notes Josep Maria Espinalt, GM of Palex Medical.
“Palex has decades of experience as a leading distributor of innovative products to medical centers across Spain,” according to Todd Wallach, CEO of MDI. “Their reputation for expert customer service and operational excellence along with their extensive customer network at leading hospitals will be major assets in driving adoption of our MRSA assay.”
The Detect-Ready MRSA assay kit has received the CE-mark certification for sale in the EU. It is available in Germany, U.K., Ireland, Switzerland, and Austria.